Psyence Biomedical Ltd (NASDAQ:PBM)’s traded shares stood at 0.36 million during the last session, with the company’s beta value hitting -0.11. At the close of trading, the stock’s price was $0.43, to imply a decrease of -1.36% or -$0.01 in intraday trading. The PBM share’s 52-week high remains $108.00, putting it -25016.28% down since that peak but still an impressive 13.95% since price per share fell to its 52-week low of $0.37. The company has a valuation of $1.96M, with an average of 0.17 million shares in intraday trading volume over the past 10 days and average of 249.06K shares over the past 3 months.

Psyence Biomedical Ltd (NASDAQ:PBM) trade information

After registering a -1.36% downside in the last session, Psyence Biomedical Ltd (PBM) has traded red over the past five days. The 5-day price performance for the stock is -21.06%, and -26.27% over 30 days. With these gigs, the year-to-date price performance is -79.43%. Short interest in Psyence Biomedical Ltd (NASDAQ:PBM) saw shorts transact 0.19 million shares and set a 1.8 days time to cover.

PBM Dividends

Psyence Biomedical Ltd has its next earnings report out in June. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.

Psyence Biomedical Ltd (NASDAQ:PBM)’s Major holders

Psyence Biomedical Ltd insiders hold 15.60% of total outstanding shares, with institutional holders owning 18.87% of the shares at 22.35% float percentage. In total, 18.87% institutions holds shares in the company.

Going by data provided on Mar 31, 2025 , AdvisorShares Trust-AdvisorShares Psychedelics ETF holds roughly 35.46 shares. This is just over 0.78% of the total shares, with a market valuation of $15388.0